Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy (busulfan, hydroxyurea) to interferon-a (IFNa), and finally to tyrosine kinase inhibitors such as imatinib. Although imatinib has profoundly improved outcomes for patients with CML, it has limitations. Most significantly, imatinib cannot eradicate CML primitive progenitors, which likely accounts for the high relapse rate when imatinib is discontinued. IFNa, unlike imatinib, preferentially targets CML stem cells. Early studies with IFNa in CML demonstrated its ability to induce cytogenetic remission. Moreover, a small percentage of patients treated with IFNa were able to sustain durable remissions after discontinuing therapy and were probably cured. The mechanisms by which IFNa exerts its antitumor activity in CML are not well understood; however, activation of leukemia-specific immunity may have a role. Some clinical studies have demonstrated that the combination of imatinib and IFNa is superior to either therapy alone, perhaps because of their different mechanisms of action. Nonetheless, the side effects of IFNa often impede its administration, especially in combination therapy. Here, we review the role of IFNa in CML treatment and the recent developments that have renewed interest in this once standard therapy for patients with CML.
INTRODUCTION TO CHRONIC MYELOID LEUKEMIA
Chronic myeloid leukemia (CML) is characterized by excessive myeloid proliferation and a recurrent cytogenetic abnormality known as the Philadelphia chromosome (Ph). The abnormality results from a balanced translocation between chromosomes 9 and 22, t(9;22)(q34; q11.2), which fuses the breakpoint cluster region (BCR) gene on chromosome 22 to the ABL gene on chromosome 9.
1,2 The resultant BCR-ABL oncogene encodes a constitutively active fusion BCR-ABL p210 oncoprotein. The activity of BCR-ABL is central to the pathogenesis of CML because it alters the proliferation, natural death processes and migration of the neoplastic cells. [3] [4] [5] As a consequence, the leukemic clone gradually replaces normal hematopoiesis. Residual normal hematopoiesis is present in the vast majority of patients with CML, but since it is suppressed, most of the blood cells are Ph þ .
OVERVIEW OF TREATMENTS FOR CML
Until the early 1980s, CML therapy was based on busulfan or hydroxyurea, which had a negligible effect on the natural course of the disease. Talpaz et al. 6, 7 carried out the first pilot clinical trial of partially pure IFNa for the management of CML followed by a larger study. The pivotal finding was that IFNa induced cytogenetic responses, which were more durable and reproducible than those induced by chemotherapy. Although initially used in the partially pure form, recombinant forms-a2a (Hoffman La Roche, Basel, Switzerland) and a2b (Merck & Co. Inc. (formerly Schering Plough), Whitehouse Station, NJ, USA)-became the dominant IFNs used in clinical studies at doses similar to those used with partially pure IFNa (that is, 2-5 MU/m 2 daily). Recombinant IFNa therapy achieved response rates similar to those observed with the purified human product. [8] [9] [10] [11] [12] [13] Results from over 1500 randomized patients demonstrated that although both IFNa and chemotherapy (hydroxyurea or busulfan) could induce hematological responses in CML, IFNa significantly improved patient survival, with a 5-year survival rate of 50-59% compared with 29-44% for patients receiving busulfan or hydroxyurea. [14] [15] [16] [17] [18] In a study of 1303 IFN-treated patients, median survival was 8.2 years for low-risk patients, 5.4 years for intermediate-risk patients and 3.5 years for high-risk patients. 19 The studies of single-agent IFNa are summarized in Table 1 . In an effort to improve outcomes, IFNa was also combined with chemotherapeutic agents, such as cytarabine, hydroxyurea and busulfan, and even with intensive chemotherapy regimens ( Table 2) . [20] [21] [22] [23] [24] [25] [26] [27] [28] With the exception of cytarabine, the combination therapies were not usually superior to IFNa alone.
To improve its pharmacokinetic characteristics, IFNa has been attached to polyethylene glycol, which protects it from proteolytic breakdown. The resulting pegylated IFNa (PegIFNa) has been approved for the treatment of chronic hepatitis B and C and melanoma. In addition, a phase I trial evaluated escalating doses of PegIFNa-2a ± cytarabine in patients with IFNa-resistant chronic phase CML (CML-CP). 29 Dose-limiting toxicity was not observed at the highest dose of 630 mg per week. The safety profile of PegIFNa was similar to that of unmodified IFNa. While phase I trials suggested that PegIFNa induced better response rates compared with the unmodified form, 29, 30 randomized trials showed mixed results. 31, 32 By 1990, the constitutive tyrosine kinase activity of BCR-ABL was linked to the pathogenesis of CML. This discovery spurred the development of the molecular-targeted therapy imatinib (Gleevec/ Glivec; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA), which proved selective for killing cells expressing the BCR-ABL protein. 33 Clinical trials with imatinib followed and demonstrated impressive response rates in patients who had not responded to IFNa therapy. Of the patients in late CML-CP, 95% achieved a complete Abbreviations: CHR, complete hematological remission; rIFNa, recombinant interferon-a.
Role of interferon in chronic myeloid leukemia M Talpaz et al hematological remission (CHR), 60% a major cytogenetic response (MCyR) and 41% a complete cytogenetic response (CCyR). 34, 35 Initiated in June of 2000, the phase III International Randomized Study of Interferon and STI571 (IRIS) was the first large-scale trial to compare imatinib (400 mg daily) with IFNa plus low-dose cytarabine, the standard of care at that time. 36 The results in 1106 patients with newly diagnosed CML-CP demonstrated that imatinib was better tolerated and induced higher CHR and CCyR rates that resulted in longer progression-free survival than IFNa. The IRIS study did not report survival differences between the treatments because 90% of patients in the IFNa arm eventually crossed over to imatinib. However, comparison with IFNa-treated historical controls indicated a significant survival advantage with imatinib. [37] [38] [39] The US Food and Drug Administration subsequently approved imatinib for the treatment of newly diagnosed patients with CML-CP. In 2010, the Food and Drug Administration approved the second-generation tyrosine kinase inhibitors (TKIs) dasatinib (100 mg daily) and nilotinib (300 mg twice daily) as frontline therapies for patients with CML-CP. Recent studies indicate that both dasatinib and nilotinib are superior to standard-dose imatinib with regard to CCyR, major molecular response (MMR), and prevention of progression to accelerated and blast phases. 40, 41 Current therapeutic guidelines also recommend the use of nilotinib or dasatinib in patients intolerant or resistant to imatinib therapy and state that IFNa 'should no longer be considered as initial therapy for CML', but could be considered in 'rare patients unable to tolerate imatinib, dasatinib or nilotinib'. 42, 43 Another treatment option for this patient population is hematopoietic stem cell transplantation, which was introduced in the 1970s. Although associated with significant morbidity and mortality, this therapy cured a substantial percentage of the patients with CML who qualified for it. In fact, transplantation is still perceived as the only curative treatment for CML. In 2007, the German CML Study Group conducted a randomized clinical trial comparing primary allogeneic hematopoietic stem cell transplantation with best available drug therapy (IFNa-based, but many patients were switched to imatinib over the course of the study) for patients with early CML-CP. 44 For the first 8 years, the drug treatment arm demonstrated better survival curves than those of the transplant arm. Beyond 8 years, the survival curves became less distinct. These results suggested that drug therapy should serve as first-line treatment for patients with CML-CP.
LIMITATIONS OF TKI TREATMENT IN CML AND EMERGING ROLES FOR IFNa
The phenomenal outcomes of the IRIS study notwithstanding, a significant number of patients will require second-line therapy as a result of intolerance to or failure of imatinib therapy. After 8 years, 45% of patients in the IRIS trial randomized to receive imatinib were no longer receiving imatinib because of toxicity (6%), suboptimal response/failure (16%) or other reasons (23%). 45 Furthermore, a small fraction of patients taking imatinib continue to progress to accelerated or blast phase every year. 45 Another significant limitation of imatinib is the inability of most CML patients to discontinue therapy and maintain their remission. 46 Rousselot et al. 47 reported that even though disease could not be detected for a median of 32 months in 12 CML patients who received imatinib, once therapy was stopped the BCR-ABL transcript was detectable in six of the patients within 1-5 months. Furthermore, the six patients who did not immediately relapse had previously taken IFNa for 29-152 months. Other studies, including IRIS, have also demonstrated improved outcomes with imatinib in patients who received or responded to prior IFNa treatment. [48] [49] [50] [51] More recently, Mahon et al. 52 demonstrated that among patients who sustained a complete molecular response to imatinib for at least 2 years (a subset of patients that constitutes a minority of all treated patients), 40% did not relapse when therapy was discontinued. In a similar patient population, Ross et al. 53 used highly sensitive nested quantitative polymerase chain reaction (PCR) and found that patients who maintained a complete molecular response after stopping imatinib harbored a stable level of BCR-ABL. Taken together, these results suggest that imatinib therapy can induce durable remissions in a small subset of patients with CML and that the addition of IFNa may broaden imatinib's therapeutic potential in CML.
EVALUATING THERAPY WITH IFNa
Kinetics and predictors of response to IFNa Patients respond more quickly to imatinib than to IFNa. Patients on IFNa therapy achieve CCyR at a median time of 19 months compared with 6 months on imatinib treatment. 54, 55 This variation may be because of the different mechanisms of action of the two drugs.
Response to IFNa depends on the phase and duration of CML disease. In general, IFNa therapy best benefitted patients with early-stage disease and favorable prognostic factors. A low-risk prognostic profile included o1 year since diagnosis, no peripheral blood basophilia, no additional cytogenetic abnormalities, Caucasian descent and age o60 years; such patients achieved higher hematologic and cytogenetic response rates with IFNa than their high-risk counterparts. 56 In addition, patients in accelerated phase and blast crisis did not typically respond to IFNa. IFNa also had limited effects in late CML-CP.
Toxicities
Acute side effects to IFNa therapy commonly present as flu-like symptoms (anorexia, fever, chills, myalgias and headaches); these are not typically dose limiting and usually resolve in a few days. Chronic side effects include fatigue, weight loss, myalgias/ arthralgias, depression and immune-mediated complications, such as autoimmune hemolytic anemia/thrombocytopenia, collagen vascular disorders, hypothyroidism and immune-mediated nephritic syndrome. Cases of cardiac dysfunction, including dysrhythmias and congestive heart failure, are rare but require immediate discontinuation of IFNa. Chronic fatigue and neurotoxicity, such as depression and cognitive impairment, are common dose-limiting side effects and typically worsen with continued treatment. 57 As these toxicities have hindered compliance with therapy, three joint prospective studies examined whether a lower dose of IFNa at 3 MU/ m 2 five times a week would be as effective as the standard dose of 5 MU/m 2 daily. 58 The studies found that overall survival and response rates did not dramatically differ between groups.
Significance of cytogenetic responses to IFNa The critical finding of the IFNa trials was the correlation between cytogenetic response and survival. IFNa treatment led to MCyR in 10-40% of patients and CCyR in 5-30% of patients. 28, 59 A group of European investigators created a registry of 317 patients with CML in CCyR after starting IFNa alone or with hydroxyurea. 54 The median time to first CCyR was 19 months. After 10 years, 72% of these patients were alive and 46% were in continuous CCyR. Similarly, Kantarjian et al. 60 analyzed the long-term significance of cytogenetic responses to IFNa-based therapies. Of the 512 patients in early chronic phase, 27% achieved a CCyR within a median time of 16 months. These responders had a survival rate of 78% at a median follow-up of 127 þ months (range, 88 þ to 191 þ months). The induced CCyR was durable; patients who maintained cytogenetic remission for more than 2 years on IFNa therapy remained in remission for an average of 6 years after discontinuing treatment. These results, along with an additional study, 61 confirmed that CCyR predicts long-term survival in patients with CML and that IFNa can induce stable remissions in some patients with CML.
IFNa MECHANISMS OF ACTION IN CML
Although IFNa has been around for many years, we still do not know how it exerts its antileukemic effects. According to in vitro studies, IFNa modulates gene expression, promotes cell differentiation and apoptosis, directly inhibits cell growth and proliferation, restores regulation by the bone marrow microenvironment and induces an immunomodulatory response. Microarray analyses have shown that IFNa can induce expression of over 300 different genes. 62 These genes encode apoptotic proteins (i.e., TRAIL, Fas, caspase-4, caspase-8 and XAF-1), anti-viral proteins (that is, PKR, 2 0 5 0 A oligoadenylate synthetase and Mx proteins), immunomodulatory proteins (that is, MHC I and II, LMP-2 and C1 inhibitor), host defense proteins (that is, PKR, IRF 1-9, interleukin-15 and interleukin-6) and transcription factors (that is, signal transducer and activator of transcription 1, signal transducer and activator of transcription 2, ISGF3-g and IRF1-7)
. 63 The precise function of many of the gene products induced by IFNa remains unknown; however, several of the identified genes encode well-known pro-apoptotic proteins, including TRAIL/Apo2L and Fas/CD95. 63 In CML progenitor cells, IFNa enhances the expression of the Fas receptor, thereby increasing cell sensitivity to Fas ligand. 64 In addition to activating apoptosis, IFNa directly targets key regulators of the cell cycle, including retinoblastoma protein, cdc25A, cyclins (cyclin D3, cyclin E and cyclin A) and cyclindependent kinases (cdk4 and cdk6). Such targeting can block and/ or lengthen the cell cycle phases, allowing cells to differentiate or undergo apoptosis. 65, 66 In bone marrow hematopoietic progenitors, IFNa directly inhibits proliferation by suppressing the production of hematopoietic stimulatory cytokines, such as granulocyte-macrophage colony-stimulating factor and interleukin-1b. It also increases the synthesis of inhibitory cytokines, including interleukin-1 receptor antagonist and transforming growth factor-b. 67 In addition, IFNa may inhibit the proliferation of CML progenitors by restoring normal hematopoietic mechanisms. In normal progenitors, b1-integrin receptors mediate cell adhesion to the bone marrow stroma, and stimulation of these receptors transmits antiproliferation signals. These two regulatory mechanisms are defective in CML progenitors, but Bhatia et al. 68 have shown that IFNa can restore them. Lastly, the growth-inhibitory effects of IFNa seem to require activation of the mitogen-activated protein kinase p38 in CML progenitors. 69, 70 IFNa treatment activates p38 by phosphorylation, which in turn leads to the transcription of IFNa-inducible genes.
In addition to directly inhibiting cell proliferation, IFNa may attenuate CML by activating host immune cells, including B and T lymphocytes, natural killer cells and antigen-presenting dendritic cells. [71] [72] [73] [74] The increased incidence of immune-mediated complications with IFNa therapy supports such immune activation. 75 Addition of IFNa both in vitro and in vivo caused CML mononuclear cells to differentiate into dendritic cells; the dendritic cells then served as antigen-presenting cells for CMLspecific peptides. 76 Similarly, in the presence of IFNa and granulocyte-macrophage colony-stimulating factor in vitro, CML bone marrow mononuclear cells differentiated into dendritic cells with specific antileukemia function. 74 This may have clinical relevance because addition of granulocyte-macrophage colonystimulating factor to treatment with IFNa in patients who failed to achieve an MCyR (n ¼ 14) improved cytogenetic responses for half of the patients. 77 Lastly, IFNa (but not imatinib) induces cytotoxic T cells (CTLs) specific for CML progenitors. 78 Given the potential benefits of combination therapy with imatinib and IFNa, a recent study investigated the effect of BCR-ABL signaling on IFNa activity in a CML cell line. 79 The study showed that expression of BCR-ABL in non-CML cells attenuated IFN signaling; however, pre-treatment of CML cells with imatinib augmented the antigrowth effects of IFNa exposure. In addition, imatinib pre-treatment enhanced signal transducer and activator of transcription 1 phosphorylation induced by IFNa. These results, in addition to providing insights into the mechanism of action of the combination therapy, may translate into a clinical strategy to increase the sensitivity of CML cells to IFNa. 84 One explanation is that IFNa puts tumor cells in a dormant state, which prevents residual leukemia cells from regenerating clinically significant leukemia.
USING MINIMAL RESIDUAL DISEASE TO DETERMINE TREATMENT PLAN
Regardless of how remission is maintained in the presence of residual disease, the studies evaluating RT-PCR analysis raised the following two questions: (1) how long should patients continue IFNa therapy once they achieve a CCyR, and (2) can RT-PCR analysis guide the decision to discontinue therapy? To address these questions, Hochhaus et al. 85 continuously monitored BCR-ABL transcript levels by RT-PCR in 54 patients who were treated with IFNa and achieved CCyR. Over a median observation period of 1.9 years, the 14 patients who relapsed demonstrated a significantly higher median BCR-ABL:ABL ratio than those who maintained a CCyR (0.49% vs 0.021%; Po0.0001). These findings suggested that the degree of residual disease could predict the probability of relapse. When IFNa was withdrawn in six of the patients, one patient relapsed and was subsequently found to possess increasing levels of MRD; thus, the authors advised that IFNa be continued at least until low levels of BCR-ABL transcripts were achieved.
The IRIS trial was the first randomized trial to evaluate molecular disease by RT-PCR in patients with CML. The results showed that BCR-ABL transcript levels fell by 3 log or greater (defined as MMR) in 57% of patients with a CCyR after 12 months of imatinib treatment. In comparison, only 24% of patients with a CCyR in the IFNa group had at least a 3-log reduction in BCR-ABL transcripts. 86 Importantly, all patients who achieved an MMR remained progression free at the 24-month follow-up. A long-term followup of the IRIS trial examined patients who achieved a CCyR with imatinib (163 out of 553 patients at 18-month follow-up). 87 Of these patients, 127 achieved an MMR by 18 months and none had CML progression at the 84-month follow-up. 87 The authors concluded that once a CCyR was reached, RT-PCR assessment of molecular disease could replace cytogenetic analysis of patient response. In support of this, Kantarjian et al. 60 reported that all 20 patients with persistent PCR-negative CML-CP maintained an MCyR at the last long-term follow-up 10 years from the first CCyR. Altogether, these studies validated molecular testing in CML and redefined how clinicians should measure patient responses and predict clinical outcomes.
To determine whether patients with sustained undetectable BCR-ABL transcript levels were fully cured or continued to generate leukemic stem cells in their bone marrow, a recent study was conducted in patients who achieved undetected MRD for 43 years with IFNa (n ¼ 3), imatinib after IFNa failure (n ¼ 2) or dasatinib after imatinib intolerance (n ¼ 1). 88 In all patients, leukemic stem cells expressing BCR-ABL were identified. At this time, whether undetected MRD correlates with risk of disease relapse is not known and warrants further investigation.
POTENTIAL RE-EMERGENCE OF IFNa USE IN CML: CURRENT DEVELOPMENTS AND FUTURE STRATEGIES
Durable responses after discontinuation of IFNa Several cases of continuous cytogenetic remission after the cessation of IFNa therapy have generated excitement about the curative potential of IFNa. 61, 89 These patients usually maintained a CCyR for more than 24 months before discontinuing IFNa and maintained remission for an average of 6 years after discontinuing therapy. Outside of allogeneic hematopoietic stem cell transplantation, this represents the closest evidence of a clinical 'cure' for CML. Note that only approximately 20% of patients who receive IFNa achieve a durable CCyR, but those who reach this milestone demonstrate prolonged survival.
Several preclinical studies provide possible reasons why imatinib may not be sufficient to cure CML. First, primitive CML cells/leukemic stem cells do not readily undergo apoptosis when exposed to imatinib, even after prolonged exposure. 90, 91 Second, CML early progenitor/stem cells persist in patients who achieve a CCyR with imatinib. 92 Thus, since imatinib does not eliminate the malignant progenitors that cause the disease, it is probably not curative in the majority of cases. These progenitors may escape imatinib toxicity because they do not depend on BCR-ABL mechanisms for survival and proliferation. 93 In support of this, a recent in vitro study demonstrated that while imatinib does inhibit the BCR-ABL kinase and its downstream signaling in CML primitive progenitors, the drug fails to facilitate death in these cells. 94 This finding implies that CML stem cells are not 'addicted' to the BCR-ABL oncogene.
In contrast to therapy with imatinib, evidence suggests that IFNa actually targets the residual leukemic stem cells that cause disease relapse. Short-term colony-forming and long-term cultureinitiating cell assays showed that IFNa was more active against primitive CML progenitors, whereas imatinib preferentially targeted more mature, differentiated CML progenitors. 95 These findings may explain why the clinical responses to IFNa are slower but more durable than those to imatinib. Imatinib acts quickly on the more differentiated progenitors that make up the bulk of the leukemia. By contrast, since IFNa targets the rare CML stem cell (o1% of the CML population), its effects may not manifest as early on in treatment. More recent data in mice have shown that IFNa administered to dormant stem cells activates and thereby sensitizes them to subsequent killing by chemotherapeutic agents. 96 A small clinical trial investigating the value of prior IFNa treatment in maintaining remission after discontinuing imatinib therapy is currently ongoing (ClinicalTrials.gov, Identifier: NCT01073436).
Combining IFNa with imatinib and second-generation TKIs To identify optimal imatinib-based regimens for CML-CP, two large multicenter, randomized treatment optimization studies were initiated: the German CML-Study IV (imatinib 400 mg vs imatinib plus IFNa (1.5-3 MU thrice weekly) vs imatinib plus cytosine arabinoside vs imatinib after IFNa failure vs imatinib 800 mg; n ¼ 1022) 97 and the French STI571 Prospective Randomized Trial (SPIRIT; imatinib 400 mg vs imatinib 600 mg vs imatinib plus cytosine arabinoside vs imatinib plus PegIFNa; n ¼ 636). 98 Of note, the German CML-Study IV used IFNa, whereas the French study used PegIFNa-2a (Pegasys; Hoffmann-La Roche Inc., Nutley, NJ, USA).
In the German CML-Study IV, recruitment to the imatinib plus cytosine arabinoside and the imatinib after IFNa failure study arms was terminated early because of feasibility and compliance issues. At 12 months, a higher rate of MMR was observed with tolerability-adapted imatinib 800 mg compared with the imatinib 400 mg ± IFNa arms (P ¼ 0.003; Table 3 ). Significantly higher rates of CCyR were also observed with imatinib 800 mg over the first 24 months, as well as superior molecular responses at the 1, 0.1 and 0.01% BCR-ABL transcript levels according to the International Scale (IS). Treatment approaches were well tolerated with similar grade 3 and 4 adverse events. The investigators suggested that the superior remission rates in the high-dose imatinib arm were a result of the strategy applied (high dose early on and maintenance around 600 mg per day according to tolerability). The earlier and faster remissions with tolerability-adapted high-dose imatinib are expected to translate into better survival with longer follow-up.
In contrast to the German CML-Study IV, the French SPIRIT study reported significantly faster and better molecular response rates with the combination of imatinib plus PegIFNa-2a compared with imatinib alone (400 and 600 mg per day) and combined with cytarabine (Table 3) . 98 Specifically, the 12-, 18-and 24-month rates and cumulative incidences of major and superior (44-log reduction in BCR-ABL:ABL transcripts) molecular responses were significantly higher in this group. Enrollment in the imatinib 600 mg and imatinib plus cytosine arabinoside arms was stopped primarily because of low rates of molecular responses and observed toxicity, respectively. Furthermore, 45% of patients discontinued PegIFNa-2a in the first year primarily because of adverse effects; however, when the dose was reduced from 90 to 45 mg per week, treatment was better tolerated. A major finding of the study was that longer duration of imatinib plus PegIFNa-2a (particularly more than 12 months) correlated with a better rate of molecular responses. However, event-free survival did not differ across all the arms of the study after 4 years of follow-up. The second part of the trial will focus on whether the earlier and faster response rates with this combination translate into better survival.
At 12-month follow-up, the incidence of MMR with imatinib 400 mg per day was 31% in CML-Study IV and 38% in SPIRIT, both of which were comparable with the 39% MMR rate observed in IRIS. In contrast, the 12-month MMR rate in the imatinib plus IFNa arm of CML-Study IV was 35% compared with 57% in the imatinib plus PegIFNa-2a arm of SPIRIT. The patient populations in the two studies were not different, and it is possible that use of the pegylated form of IFNa, which was designed to have a longer half-life in the blood, improved the efficacy of the combination in the SPIRIT trial.
Three smaller phase II studies of imatinib plus PegIFNa-2b (PegIntron; Merck) reported discordant results. The Nordic group study (n ¼ 112) compared the combination of PegIFNa-2b 50 mg per week and imatinib 400 mg per day with imatinib 400 mg per day alone in patients with low-or intermediate-risk CML. 99 The MMR rate was significantly higher in the combination arm (82%) compared with the monotherapy arm (54%) at 12 months. Even a short exposure to PegIFNa-2b (3-6 months) improved response to imatinib. Notably, 34 of the 56 patients in the combination arm discontinued PegIFNa-2b, mainly owing to adverse events, such as neutropenia and constitutional symptoms. To manage adverse events, the starting dose of PegIFNa-2b (50 mg per week) was lowered to 30 mg per week. Of those who continued therapy with PegIFNa-2b for more than 12 months, 91% achieved an MMR vs 58% in the imatinib monotherapy arm. The second two-arm study (n ¼ 94) examined the addition of PegIFNa-2b (0.5 mg/kg per week) and granulocyte-macrophage colony-stimulating factor to high-dose imatinib (800 mg per day) vs the continuation of high-dose imatinib alone in patients with early CML-CP. 100 Unlike the Nordic and SPIRIT trials, this study found no differences in the cytogenetic or molecular response rates between the two arms. Owing to treatment-related toxicity, the combination arm had a high dropout rate, which may have hampered potential benefits of the immunotherapy. Adherence to PegIFNa-2b was also very low (13%) in an earlier study of imatinib plus PegIFNa-2b conducted by the Italian Cooperative Study Group. 101, 102 The starting doses of PegIFNa-2b (50, 100 and 150 mg per week) were Role of interferon in chronic myeloid leukemia M Talpaz et al likely too high in combination with imatinib, leading to grade 3 or 4 neutropenia in 63% and grade 3 or 4 non-hematologic adverse events in 52% of patients. The German, SPIRIT and Nordic studies, which used lower doses of IFNa, reported comparatively fewer grade 3 and 4 hematological and non-hematological adverse events in patients taking imatinib plus IFNa. A retrospective analysis of the Italian study showed that CCyR and MMR rates were higher in patients receiving the combination at early time points, but were comparable with the imatinib-only arm at longer times. The durability of responses, event-free survival and overall survival were also similar between the two arms. 102, 103 Interestingly, the early and fast response rates with imatinib 800 mg and with imatinib plus PegIFNa are similar to those recently reported for the second-generation TKIs dasatinib 41 and nilotinib. 40 Studies investigating the combination of IFNa with nilotinib or dasatinib are ongoing. A phase I German study (NICOLI) is investigating the maximum-tolerated dose of low-dose IFNa in combination with nilotinib in patients with imatinibresistant CML-CP (ClinicalTrials.gov, Identifier: NCT01220648). The phase II French NILOPEG trial (ClinicalTrials.gov, Identifier: NCT01294618) is studying the efficacy of nilotinib plus PegIFNa2a (45 mg per week) in the first-line setting. The phase II German CML-Study V (ClinicalTrials.gov, Identifier: NCT01657604; EudraCT, Number: 2010-024262-22), which was activated in August 2012, is comparing nilotinib, nilotinib plus IFNa, maintenance with nilotinib and maintenance with IFNa (four arms). Two small phase II studies are investigating the value of adding PegIFNa-2a (45 mg per week in one study and 180 mg per week in the other) for 2 years to the treatment regimen of patients who achieved CCyR and p0.5% BCR-ABL:ABL transcript with imatinib, nilotinib or dasatinib (ClinicalTrials.gov, Identifier: NCT01392170 and NCT00573378).
Value of IFNa in patients with the T315I mutation Treatment of patients with the T315I mutation (threonine-toisoleucine mutation at amino acid 315) in BCR-ABL is challenging, as this mutation confers resistance to treatment with imatinib, as well as second-generation TKIs. The frequency of this mutation ranges from 2-20% of imatinib-resistant CML patients. The National Comprehensive Cancer Network guidelines recommend hematopoietic stem cell transplantation, if applicable, or participation in a clinical trial for this patient population. 104 Currently, a number of agents are under investigation, including ponatinib 105 (a reversible Abl-Src inhibitor), DCC-2036 (a switch-pocket inhibitor) and homoharringtonine (omacetaxine). 106 Although no clinical studies have investigated the value of IFNa in treating patients with the T315I mutation, two case reports have recently been published. One patient with the T315I mutation achieved a CCyR after 12 months of treatment with imatinib (400 mg per day), but developed resistance after 18 months of treatment. The patient was treated with a combination of imatinib and IFNa (6 MU per week). After 51 months of combination treatment, he achieved MMR, and the T315I mutation was not detected by direct sequencing or pyrosequencing. While the patient experienced grade 2 anemia and grade 1 neutropenia and thrombocytopenia, he could continue the treatment with no dose reduction. 107 In the second case, the patient was treated with KW-2449, a T315I-specific inhibitor, after losing the CCyR induced by 800 mg per day imatinib. While KW-2449 appeared to reverse the T315I mutation, his response did not improve; furthermore, he developed the F359I mutation. On switching to combination treatment with dasatinib (50 mg twice daily) and PegIFNa (9 MU per day), the patient achieved a CCyR and an MMR with a BCR-ABL:ABL ratio of 0.05 after 4 months. 108 These reports point to the potential value of IFNa in eradicating resistance to TKI treatment in the presence of the T315I mutation. More robust data are needed to confirm these treatment benefits.
Induction of CML-specific immunity by IFNa and implications for maintenance therapy As mentioned above, IFNa is known to activate leukemia-specific immunity, but the underlying mechanism is still not well understood. One current hypothesis is based on early work by 109 examining the immunogenicity of proteinase 3, a serine protease highly expressed in various myeloid leukemia cells, including CML. A peptide derived from proteinase 3 known as PR1 was identified with high affinity for HLA-A.2.1. Of significance, CTLs specific for PR1 eliminated CML progenitors, but not normal marrow cells. A subsequent investigation detected circulating PR1-specific CD8 þ T cells in 11 out of 12 IFNa responders, but not in non-responders (0 of 7). 73 Kanodia et al.
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recently hypothesized that IFNa induces stable remissions at least in part by increasing the expression of PR1 in CML cells. As IFNa induces the expansion of self-renewing memory CTLs specific for PR1, the PR1-expressing CML progenitors become a prime target for immune-mediated killing. 110 In support of this, PR1-CTLs were found to be increased in CML patients with a CCyR after IFNa cessation. Moreover, the PR1-CTLs secreted IFNg in response to stimulation with PR1 peptide. By contrast, PR1-CTLs from the three patients who relapsed after IFNa withdrawal lost their ability to secrete IFNg. 110 These findings suggest that loss of functional PR1-CTLs may contribute to relapse in patients with CML.
Given the potential for developing imatinib resistance and/or intolerance with continued imatinib treatment, maintenance therapy with IFNa may allow patients to discontinue imatinib by keeping CML progenitors suppressed. A recent report on the use of PegIFNa-2a maintenance after induction treatment with imatinib and PegIFNa-2a demonstrated sustained remission in 15 out of 20 CML-CP patients at a median of 2.4 years after imatinib discontinuation. 111 This impressive outcome was thought to involve a T-cell response because proteinase 3 mRNA levels and frequencies of PR1-CTLs increased during maintenance therapy with IFNa. To minimize toxicity from long-term IFNa use, a later study administered PegIFNa 9 months before and 3 months after imatinib discontinuation. 112 This regimen improved the remission status of 5 of the 11 patients over a median follow-up of 47 months. These studies support further exploration of the role of IFNa consolidation or maintenance therapy after TKI induction.
OPTIMIZING THERAPY: EARLY RESPONSE PREDICTORS
Before the imatinib era, the Hasford or Euro score (developed from a study of 1303 IFNa-treated patients) was used to predict prognosis at diagnosis based on spleen size, percent blasts, age, platelet count, eosinophilia and basophilia. 19 A new prognostic score called EUTOS (European Treatment and Outcome Study score) has since been developed to predict clinical responses to imatinib. 113 The score was developed from a study of 2060 patients treated with imatinib, including imatinib at 800 mg and in combination with IFNa. Using only two variables (spleen size and basophil percentage in peripheral blood), the score discriminates between high-and low-risk groups and predicts that 34% of highrisk patients will fail to achieve CCyR. This score predicts treatment failure with better sensitivity and specificity than the Sokal or Euro scores. 113 A further advance is response prediction at 3 months. CML patients at risk of progression are candidates for change of therapy, including addition of IFNa to front-line TKI treatments. Identifying patient response to a drug early on in the treatment is key for optimizing treatment protocols. 114 Early response predictors for CML are summarized in Table 4 . Patients who achieve a cytogenetic remission (CCyR or MCyR) or reach a BCR-ABL level of o10% (IS) after 3 months have significantly better overall survival after 5 years (95% vs 87%). 55, 115, 116 This will likely replace the current definition of optimal response to imatinib at 3 months, which requires CHR and o95% Ph þ metaphases. 42 For newly diagnosed patients treated with IFNa, achievement of CHR within 3 months predicted MCyR. 117 
CONCLUSIONS
The reduced tolerability and slower response kinetics of IFNa compared with TKIs have reduced the enthusiasm for this therapy. However, therapy with imatinib and other TKIs may be limited by drug resistance, intolerance and, when therapy is discontinued, relapse. In contrast to targeted therapies, IFNa has a broad range of therapeutic effects that may reduce the likelihood of resistance or relapse, especially when used in combination with other CML therapies. These factors along with the proven efficacy of pegylated forms of IFNa, even at low doses, have revived interest in IFNa therapy for CML.
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